




RealRate

PHARMACEUTICAL 2016

Supernus Pharmaceuticals INC
Rank 123 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Supernus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Supernus Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 67% points. The greatest weakness of Supernus Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 310%, being 47% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	105,977
Cost of Goods Sold	0
Intangible Assets	976
Liabilities, Current	56,097
Liabilities, Non-Current	4,325
Other Assets	77,903
Other Compr. Net Income	-334
Other Expenses	9,379
Other Liabilities	9,433
Other Net Income	-2,693
Other Revenues	144,427
Property and Equipment	3,874
Research and Development	29,135
Selling, General and Administrative Expense	89,204

Output Variable	Value in 1000 USD
Assets	188,730
Liabilities	69,855
Expenses	127,718
Revenues	144,427
Stockholders Equity	118,875
Net Income	14,016
Comprehensive Net Income	13,849
BaseVar	266,878
ECR before LimitedLiability	211%
Economic Capital Ratio	310%